Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

ASTRAZENECA AB

Home Clinical Trial Sponsors and OrganizationsASTRAZENECA AB

ASTRAZENECA AB

ACTIVE

CALLE RAIMUNDO FERNANDEZ VILLAVERDE 63, Madrid, Spainwww.astrazeneca.seSubsidiary

Part of 阿斯利康

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

3243

2712 active

Approvals

340

Total approvals

Agencies

6

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

1968

60.7%

Phase 3

309

9.5%

Phase 2

108

3.3%

Not Applicable

40

1.2%

Phase 4

11

0.3%

Phase 1/2

2

0.1%

Phase 2/3

2

0.1%

Phase 3 4

2

0.1%

Unknown

1

0.0%

Trial Status Distribution

Recruiting

422

13.0%

Suspended

8

0.3%

Withdrawn

2

0.1%

Active, not recruiting

2655

81.9%

Unknown

11

0.3%

Completed

81

2.5%

Not yet recruiting

57

1.8%

Clinical Trials

Trials sponsored by this organization (3243)

A trial to learn how safe newer immunotherapy drugs are and how well they work with or without other anti-cancer drugs in adults with advanced, unresectable non-small cell lung cancer

Jan 202711 participants

A trial to learn how safe anifrolumab is, how it moves throughout the body over time, and how it affects the body of adults with systemic lupus erythematosus

Oct 20261 participant

A study to learn how safe AZD6621 is, how well it works, and how it moves throughout the body over time, in adult male participants with Metastatic Prostate Cancer

Oct 202645 participants

A trial to test the effectiveness and safety of an investigational drug called Surovatamig (AZD0486) when taken with the already marketed drug Rituximab in comparison to standard treatments already in use for patients who have Follicular Lymphoma and have never been treated before

Sep 202615 participants

A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Surovatamig in Adults With Antibody-mediated Kidney Disease

Sep 202617 participants

A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared with Rosuvastatin on LDL-C in Patients with Hypercholesterolaemia.

Sep 202660 participants

A master protocol to investigate efficacy and safety of elecoglipron in participants with obesity or overweight with or without type 2 diabetes mellitus.

Active, not recruiting

Sep 2026180 participants

A Modular Open-label, Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Ascending Doses of AZD4956 as Monotherapy, and in Combination with Anti-Cancer Agents in Participants with Advanced/Metastatic Homologous Recombination Repair Defective Solid Tumours (PARTHENON)

Sep 202610 participants

Page 1 of 406

Approvals

Approvals by Agency

NMPA

National Medical Products Administration

101

Approvals

EMA

European Medicines Agency

87

Approvals

PHILIPPINES

Philippines FDA

18

Approvals

SFDA

Saudi Food and Drug Authority

31

Approvals

NPRA

National Pharmaceutical Regulatory Agency

26

Approvals

CIMA_AEMPS

Spanish Agency for Medicines and Medical Devices

77

Approvals

Recent Approvals

CALQUENCE 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

LYNPARZA 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

IMFINZI 50 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSION

IMFINZI 50 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSION

Osimertinib Mesylate Tablets

Osimertinib Mesylate Tablets

Osimertinib Mesylate Tablets

Osimertinib Mesylate Tablets

PULMICORT TURBUHALER 200MCG/DOSE

PULMICORT TURBUHALER 100MCG/DOSE

News

HRSA Approves Eight Drug Companies for 340B Rebate Model Pilot Program Starting January 2025

- The Health Resources and Services Administration has approved eight pharmaceutical companies to participate in the 340B Rebate Model Pilot Program, which will begin on January 1, 2025. - Nine drugs from major manufacturers including Bristol Myers Squibb's Eliquis, Novo Nordisk's Novolog, and Janssen's Stelara will be included in the voluntary rebate program. - The pilot program allows drugmakers to provide 340B discounted pricing through a rebate model rather than upfront discounts, with HRSA planning to evaluate the program for at least one year. - The initiative follows legal challenges from Johnson & Johnson, Bristol Myers Squibb, and Eli Lilly regarding HRSA's authority to review and approve rebate models in the 340B program.

On this page

Overview
Clinical Trials3243
Approvals340
News1

Back to Organizations